z-logo
Premium
A case of tumour necrosis factor‐α inhibitor‐ and rituximab‐induced plantar pustular psoriasis that completely resolved with tocilizumab
Author(s) -
Jayasekera P.,
Parslew R.,
AlSharqi A.
Publication year - 2014
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.13146
Subject(s) - medicine , rituximab , tocilizumab , rheumatoid arthritis , psoriasis , psoriatic arthritis , tumor necrosis factor alpha , monoclonal , methotrexate , dermatology , arthritis , monoclonal antibody , immunology , antibody
Summary Rituximab, a chimeric B ‐cell‐depleting monoclonal antibody, is a well‐established therapy for rheumatoid arthritis. It is emerging that classical psoriatic lesions and plantar pustular psoriasis ( PPP ) are cutaneous side‐effects of this drug. Antitumour necrosis factor (anti‐ TNF ) therapies have multiple documented side‐effects including PPP and psoriasis. We report a patient who has rheumatoid arthritis, who failed on anti‐ TNF therapies and then was commenced on rituximab. Subsequently she developed localized PPP . Due to deterioration of her joint disease she was switched to the interleukin‐6 blocker tocilizumab, and the PPP resolved.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here